Metreleptin
Contents
Description
Metreleptin is a recombinant analog of human leptin used as replacement therapy for complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. It helps regulate metabolic abnormalities including severe hypertriglyceridemia and diabetes mellitus. The drug is indicated for drug-induced lipodystrophy when associated with metabolic complications.
Indications & Therapeutic Use
Generalized lipodystrophy, drug-induced lipodystrophy with metabolic complications
Linked Diseases:
Global Availability (6 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Metreleptin — GNH India
10 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Metreleptin products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | Metreleptin |
| Brands | 1 brand available |
| Active Ingredient | Metreleptin |
| Drug Class | Generalized lipodystrophy |
| Manufacturer | Amryt Pharma |
| Dosage Forms | Subcutaneous injection, 11.3mg powder for reconstitution |
| Medical Code | A16AX08 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 21 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00677313 |
| Countries | 6 countries |